Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iduna Fichtner

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Cancer Research|April 5, 2005
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody constructBernd Schlereth, Iduna Fichtner, Grit Lorenczewski, et al.
Translational Oncology|January 28, 2014
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of DrugsNadine Löschmann, Martin Michaelis, Florian Rothweiler, et al.
Frontiers in Oncology|December 25, 2023
GIPC1 regulates MACC1-driven metastasisFranziska Siegel, Hannes Schmidt, Manisha Juneja, et al.
Journal of Medicinal Chemistry|December 3, 2002
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compoundFelix Kratz, André Warnecke, Karin Scheuermann, et al.
Frontiers in Oncology|April 28, 2023
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signaturesJoshua Alcaniz, Lars Winkler, Mathias Dahlmann, et al.
Molecular Cancer Therapeutics|December 7, 2002
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazolesTracey D Bradshaw, Michael C Bibby, John A Double, et al.
Cancers|December 23, 2023
Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingDiana Behrens, Ulrike Pfohl, Theresia Conrad, et al.
Molecular Immunology|September 6, 2005
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumorsKlaus Brischwein, Bernd Schlereth, Benjamin Guller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIPLuke Piggott, Andreia Silva, Timothy Robinson, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|July 22, 2014
Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse modelsMaribel G Vallespí, Gilmara Pimentel, Ania Cabrales-Rico, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Cancer Research|April 5, 2005
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody constructBernd Schlereth, Iduna Fichtner, Grit Lorenczewski, et al.
Translational Oncology|January 28, 2014
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of DrugsNadine Löschmann, Martin Michaelis, Florian Rothweiler, et al.
Frontiers in Oncology|December 25, 2023
GIPC1 regulates MACC1-driven metastasisFranziska Siegel, Hannes Schmidt, Manisha Juneja, et al.
Journal of Medicinal Chemistry|December 3, 2002
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compoundFelix Kratz, André Warnecke, Karin Scheuermann, et al.
Frontiers in Oncology|April 28, 2023
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signaturesJoshua Alcaniz, Lars Winkler, Mathias Dahlmann, et al.
Molecular Cancer Therapeutics|December 7, 2002
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazolesTracey D Bradshaw, Michael C Bibby, John A Double, et al.
Cancers|December 23, 2023
Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingDiana Behrens, Ulrike Pfohl, Theresia Conrad, et al.
Molecular Immunology|September 6, 2005
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumorsKlaus Brischwein, Bernd Schlereth, Benjamin Guller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2018
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIPLuke Piggott, Andreia Silva, Timothy Robinson, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|July 22, 2014
Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse modelsMaribel G Vallespí, Gilmara Pimentel, Ania Cabrales-Rico, et al.
Pageof 12